Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the fourteen brokerages that are presently covering the firm, Marketbeat Ratings reports. Four analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $81.33.
KROS has been the subject of a number of recent analyst reports. TD Cowen downgraded shares of Keros Therapeutics from a "buy" rating to a "hold" rating in a research report on Thursday, December 12th. Cantor Fitzgerald reissued an "overweight" rating on shares of Keros Therapeutics in a research note on Friday, November 22nd. Jefferies Financial Group initiated coverage on shares of Keros Therapeutics in a report on Tuesday, November 5th. They issued a "buy" rating on the stock. Scotiabank decreased their price target on Keros Therapeutics from $77.00 to $44.00 and set a "sector outperform" rating for the company in a report on Friday, December 13th. Finally, BTIG Research downgraded Keros Therapeutics from a "buy" rating to a "neutral" rating in a research note on Thursday, December 12th.
View Our Latest Research Report on KROS
Keros Therapeutics Stock Down 4.8 %
Shares of KROS stock traded down $0.87 during trading hours on Wednesday, hitting $17.13. 2,083,669 shares of the company's stock traded hands, compared to its average volume of 478,355. Keros Therapeutics has a 12 month low of $15.67 and a 12 month high of $73.00. The stock has a market cap of $693.88 million, a PE ratio of -3.29 and a beta of 1.20. The stock's 50 day simple moving average is $56.64 and its 200 day simple moving average is $52.06.
Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company had revenue of $0.39 million for the quarter. During the same period in the prior year, the company posted ($1.33) earnings per share. The firm's revenue was up 4750.0% compared to the same quarter last year. As a group, equities research analysts expect that Keros Therapeutics will post -5.26 EPS for the current fiscal year.
Hedge Funds Weigh In On Keros Therapeutics
A number of large investors have recently modified their holdings of the company. KBC Group NV raised its holdings in Keros Therapeutics by 52.0% during the third quarter. KBC Group NV now owns 1,263 shares of the company's stock worth $73,000 after buying an additional 432 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company's stock worth $77,000 after acquiring an additional 280 shares in the last quarter. Values First Advisors Inc. acquired a new stake in shares of Keros Therapeutics in the 3rd quarter worth about $89,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Keros Therapeutics in the 2nd quarter valued at about $128,000. Finally, LMR Partners LLP bought a new position in Keros Therapeutics in the 3rd quarter valued at about $213,000. 71.56% of the stock is currently owned by institutional investors.
About Keros Therapeutics
(
Get Free ReportKeros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.
Featured Articles
Before you consider Keros Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Keros Therapeutics wasn't on the list.
While Keros Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.